Uni­ver­si­ty was tipped off to pos­si­ble unau­tho­rized tri­als of her­pes vac­cine

WASH­ING­TON — The uni­ver­si­ty that em­ployed a con­tro­ver­sial her­pes vac­cine re­searcher has told the fed­er­al gov­ern­ment it learned last sum­mer of the pos­si­bil­i­ty of his il­le­gal ex­per­i­men­ta­tion on hu­man sub­jects. But South­ern Illi­nois Uni­ver­si­ty did not pub­licly dis­close the tip or its find­ings about re­searcher William Hal­ford’s mis­con­duct for months, ac­cord­ing to a memo ob­tained by Kaiser Health News.

Last week, Kaiser Health News re­port­ed that Hal­ford con­duct­ed an ex­per­i­ment in which he vac­ci­nat­ed pa­tients in US ho­tel rooms in 2013 with­out any safe­ty over­sight and in vi­o­la­tion of US laws, ac­cord­ing to pa­tients and emails they pro­vid­ed to KHN to sup­port their al­le­ga­tions.

They told KHN those in­jec­tions oc­curred three years be­fore Hal­ford test­ed a her­pes vac­cine he cre­at­ed on hu­man sub­jects in a house in St. Kitts in 2016, again with­out rou­tine safe­ty over­sight. Hal­ford died of can­cer at the end of June.

While the uni­ver­si­ty has re­fused to re­spond to ques­tions about the 2013 in­jec­tions, an Oct. 16 memo to the fed­er­al gov­ern­ment ob­tained by KHN un­der open-records law shows that SIU learned of such pos­si­ble ac­tiv­i­ty at the end of Ju­ly. Ac­cord­ing to the memo, Ra­tio­nal Vac­cines, the com­pa­ny that Hal­ford co-found­ed, and an­oth­er SIU pro­fes­sor dis­closed that “hu­man sub­jects re­search might have oc­curred pri­or to the … clin­i­cal tri­al in St. Kitts.”

SIU re­port­ed in the memo to the De­part­ment of Health and Hu­man Ser­vices and the Food and Drug Ad­min­is­tra­tion that its in­sti­tu­tion­al re­view board, or IRB, found Hal­ford’s ac­tiv­i­ties to be a “se­ri­ous non­com­pli­ance” and said it rec­om­mend­ed the uni­ver­si­ty con­duct a “con­fi­den­tial” in­ves­ti­ga­tion to de­ter­mine if he com­mit­ted any oth­er mis­con­duct.

“Dr. Hal­ford will­ful­ly and in­ten­tion­al­ly en­gaged in hu­man sub­jects re­search with­out the ap­proval and over­sight of the IRB, in vi­o­la­tion of IRB poli­cies and in vi­o­la­tion of ap­plic­a­ble law and reg­u­la­tion,” SIU wrote in the memo.

Pre­vi­ous­ly, the uni­ver­si­ty had said it was not re­spon­si­ble for Hal­ford’s St. Kitts tri­al be­cause he con­duct­ed it in­de­pen­dent­ly through Ra­tio­nal Vac­cines.

Be­fore re­leas­ing the memo to KHN, the uni­ver­si­ty blacked out some of the de­tails. It’s un­clear whether the “se­ri­ous non­com­pli­ance” in­volved the 2013 in­jec­tions or some oth­er unau­tho­rized hu­man sub­ject re­search.

“This is a very se­ri­ous mat­ter for the uni­ver­si­ty,” said Robert Kl­itz­man, a doc­tor and di­rec­tor of the mas­ter’s pro­gram in bioethics at Co­lum­bia Uni­ver­si­ty in New York.

Kl­itz­man said the Of­fice for Hu­man Re­search Pro­tec­tions (OHRP), the HHS di­vi­sion that over­sees com­pli­ance with rules on hu­man tri­als, could halt all of the uni­ver­si­ty’s re­search as a re­sult of the find­ing. The Na­tion­al In­sti­tutes of Health could al­so freeze its fund­ing to SIU, he added, even though Hal­ford’s re­search was not fed­er­al­ly fund­ed.

OHRP and the FDA said they have poli­cies of not dis­cussing po­ten­tial or on­go­ing in­ves­ti­ga­tions. SIU did not re­spond to ques­tions.

Sev­er­al par­tic­i­pants from both tri­als told KHN they have asked SIU for help.They said Tues­day that they felt the uni­ver­si­ty should be in­form­ing them of its in­ves­ti­ga­tion in­to unau­tho­rized ex­per­i­ments and its find­ings.

“Hal­ford test­ed his vac­cine on hu­mans us­ing SIU’s fa­cil­i­ties and re­sources,” said one Col­orado woman who has tried to talk to the uni­ver­si­ty about her ex­pe­ri­ence in the St. Kitts tri­al. “They [SIU] de­ny know­ing any­thing about it. SIU hasn’t been very forth­com­ing.”

Kl­itz­man said the uni­ver­si­ty did have a re­spon­si­bil­i­ty to the par­tic­i­pants who were in­ject­ed with Hal­ford’s vac­cine. Two of them — in­clud­ing the Col­orado woman — have filed so-called ad­verse event com­plaints with the FDA, say­ing that Hal­ford’s vac­cine may have caused side ef­fects.

“Eth­i­cal­ly, the uni­ver­si­ty should con­tact the par­tic­i­pants to let them know that some par­tic­i­pants have de­vel­oped ad­verse events,” he said.


By Marisa Tay­lor. Orig­i­nal­ly post­ed at Kaiser Health News, a na­tion­al health pol­i­cy news ser­vice that is part of the non­par­ti­san Hen­ry J Kaiser Fam­i­ly Foun­da­tion.

Martin Shkreli [via Getty]

Pris­on­er #87850-053 does not get to add drug de­vel­op­er to his list of cred­its

Just days after Retrophin shed its last ties to founder Martin Shkreli, the biotech is reporting that the lead drug he co-invented flopped in a pivotal trial. Fosmetpantotenate flunked both the primary and key secondary endpoints in a placebo-controlled trial for a rare disease called pantothenate kinase-associated neurodegeneration, or PKAN.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

We­bi­nar: Re­al World End­points — the brave new world com­ing in build­ing fran­chise ther­a­pies

Several biopharma companies have been working on expanding drug labels through the use of real world endpoints, combing through the data to find evidence of a drug’s efficacy for particular indications. But we’ve just begun. Real World Evidence is becoming an important part of every clinical development plan, in the soup-through-nuts approach used in building franchises.

I’ve recruited a panel of 3 top experts in the field — the first in a series of premium webinars — to look at the practical realities governing what can be done today, and where this is headed over the next few years, at the prodding of the FDA.

ZHEN SU — Merck Serono’s Senior Vice President and Global Head of Oncology
ELLIOTT LEVY — Amgen’s Senior Vice President of Global Development
CHRIS BOSHOFF — Pfizer Oncology’s Chief Development Officer

A premium subscription to Endpoints News is required to attend this webinar. Please upgrade to either an Insider or Enterprise plan for access. Already have Endpoints Premium? Please sign-in below. You can contact our Subscriptions team at help@endpointsnews.com with any issues.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Hal Barron. GSK

GSK's Hal Bar­ron her­alds their sec­ond pos­i­tive piv­otal for cru­cial an­ti-BC­MA ther­a­py, point­ing to a push for quick OKs in a crowd­ed field

Hal Barron has his second positive round of Phase III data in hand for his anti-BCMA antibody drug conjugate belantamab mafodotin (GSK2857916). And GSK’s research chief says the data paves the way for their drive in search of an FDA approval for treating multiple myeloma.

It’s hard to overestimate the importance of this drug for GSK, a cornerstone of Barron’s campaign to make a dramatic impact on the oncology market and provide some long-lost excitement for the pharma giant’s pipeline. They’re putting this BCMA program at the front of that charge — looking to lead a host of rivals all aimed at the same target.

We don’t know what the data are yet, but DREAMM-2 falls on the heels of a promising set of data delivered 5 months ago for DREAMM-1. There investigators noted that complete responses among treatment-resistant patients rose to 15% in the extra year’s worth of data to look over, with a median progression-free survival rate of 12 months, up from 7.9 months reported earlier. The median duration of response was 14.3 months.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Why would Am­gen want to buy Alex­ion? An­a­lysts call hot­ly ru­mored takeover un­like­ly, but seize the mo­ment

A rumor that Amgen is closing in on buyout deal for Alexion has sparked a guessing game on just what kind of M&A strategy Amgen is pursuing and how much Alexion is worth.

Mizuho analyst Salim Syed first lent credence to the report out of the Spanish news outlet Intereconomía, which said Amgen is bidding as much as $200 per share. While the source may be questionable, “the concept of this happening doesn’t sound too crazy to me,” he wrote.

FDA asks why No­var­tis took two months to launch for­mal in­ter­nal probe, af­ter AveX­is flagged da­ta ma­nip­u­la­tion

And the plot thickens. Novartis $NVS officials are reportedly now scrambling to explain to the FDA why it took them two months to open an internal investigation into data discrepancies for their $2.1 million gene-therapy for spinal muscular dystrophy — the world’s most expensive drug.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.

Build­ing on suc­cess­ful PD-1 pact, Eli Lil­ly li­cens­es di­a­betes drug to Chi­nese part­ners at In­novent

Eli Lilly is expanding its partnership with China’s Innovent in a deal involving a diabetes drug sitting in its Phase I reserves.

The two companies had jointly developed one of China’s first homegrown PD-1 agents, scoring an approval for Tyvyt (sintilimab) late last year for relapsed/refractory classical Hodgkin’s lymphoma. This time around, Lilly is out-licensing a piece of its diabetes pipeline, a leading franchise that has historically produced the top-selling Trulicity and Humalog.

Am­gen, Al­ler­gan biosim­i­lar of Roche's block­buster Rit­ux­an clears an­oth­er US piv­otal study 

Novartis $NVS may have given up, but Amgen $AMGN and Allergan $AGN are plowing ahead with their knockoff of Roche’s blockbuster biologic Rituxan in the United States.

Their copycat, ABP 798, was found to have a clinically equivalent impact as Rituxan — meeting the main goal of the study involving CD20-positive B-cell non-Hodgkin’s lymphoma patients. This is the second trial supporting the profile of the biosimilar. In January, it came through with positive PK results in patients with rheumatoid arthritis.

UP­DAT­ED: An em­bold­ened As­traZeneca splurges $95M on a pri­or­i­ty re­view vouch­er. Where do they need the FDA to hus­tle up?

AstraZeneca is in a hurry.

We learned this morning that the pharma giant — not known as a big spender, until recently — forked over $95 million to get its hands on a priority review voucher from Sobi, otherwise known as Swedish Orphan Biovitrum.

That marks another step down on price for a PRV, which allows the holder to slash 4 months off of any FDA review time.

Endpoints News

Basic subscription required

Unlock this story instantly and join 58,000+ biopharma pros reading Endpoints daily — and it's free.